HCV Forecast: Merck, AbbVie Next-Gen Data Not Overtaking Gilead
Executive Summary
Gilead's ASTRAL study data at AASLD represent a "shock-and-awe" campaign, setting up the company for continued HCV dominance over several competitors, Wall Street analyst asserts.